Source comparison
BPC-157 Bioavailability: Route Comparison
Subcutaneous injection 80–85% None (bypasses GI tract) 45–90 minutes Systemic tissue repair, tendon/ligament healing Gold standard for systemic delivery. Highest bioavailability with predictable pharmacokinetics Gastric instillation (research) 90–95% (local mu
This comparison does not assign a generated winner or score.
- Subcutaneous injection
- 80–85%
- None (bypasses GI tract)
- 45–90 minutes
- Systemic tissue repair, tendon/ligament healing
- Gold standard for systemic delivery. Highest bioavailability with predictable pharmacokinetics
- Gastric instillation (research)
- 90–95% (local mucosal uptake)
- Minimal (direct contact with mucosa)
- 10–30 minutes
- Gastric ulcer repair, GI mucosal protection
- Most effective for local GI effects but impractical outside research settings
- Oral capsules (unprotected)
- <1%
- Full gastric and pancreatic degradation
- N/A (negligible absorption)
- None. Ineffective route
- Complete degradation before absorption. No therapeutic value
- Oral capsules (enteric-coated)
- 5–8% (optimistic estimate)
- High (pancreatic proteases in duodenum)
- 90–120 minutes
- Convenience over efficacy
- Marginal improvement over unprotected oral. Still majority degradation
- Intraperitoneal (research only)
- ~100%
- None
- 20–40 minutes
- Controlled research trials
- Not applicable for human therapeutic use